/Investor DB

BlueYard Capital — 2024 Investments

5 investments dated 2024 · listed companies and verified rows first · show all

Agnosticagnostic.engineeringinSeed · Mar 2024 · $2M

Agnostic is a data and AI consultancy that designs and operates high-performance ClickHouse clusters, real-time data pipelines, and production LLM/RAG systems for clients across industries.

AI & Machine LearningData & InfrastructureDeveloper Tools

Didier Franc(Founder)in

Co-investorsKima VenturesTRGC

Cptxcptx.bioinSep 2024 · $29M

CPTx is a genetic medicines company developing in vivo therapies using immune-silent, redosable single-stranded DNA technology.

BiotechDeep TechHealthtechMedical Devices

Hendrik Dietzin

ExpressionEditsexpressionedits.comMay 2024 · $13M

ExpressionEdits builds a computational platform, the Genetic Syntax Engine, that uses AI and intron-based transgene design to improve protein expression for therapeutic applications.

AI & Machine LearningBiotechDeep Tech

Dr. Liliana Antunes(Group Leader, RNA Technologies; Co-founder)Kärt Tomberg(CEO; Co-founder; Director)inProf. Allan Bradley(Co-founder; Non-Executive Director)

Co-investorsHAWKTAILOctopus VenturesAcequia Capital (AceCap)Amino CollectiveredalpineWilbe Capital

MetaPalsmetapals.petin𝕏Sep 2024

Singapore-based maker of a browser extension whose AI-driven, blockchain-backed virtual pets live on the user's screen.

Crypto & Web3FintechGamingSingapore, SG

Co-investorsTechstarsAcequia Capital (AceCap)Protocol Labs

Transcripta Biotranscriptabio.comin𝕏Apr 2024

Transcripta Bio develops medicines for patients with serious diseases by mapping how molecules affect human cells at single-cell resolution.

AI & Machine LearningBiotechDeep Tech

Co-investorsJAZZ Venture PartnersARCH Venture PartnersDCVC BioInsight PartnersMayo Clinic Ventures

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.